Date: 2011-09-29
Type of information: Grant
Company: NeuroVive Pharmaceutical (Sweden)
Investors: Eureka Eurostars program
Amount: €1 million
Funding type: grant
Planned used: The Eurostars program has awarded NeuroVive Pharmaceutical and to-BBB technologies, two highly innovative European Small and Medium Enterprises (SMEs), a grant of approximately €500,000 each. This grant supports their joint preclinical development program on a potential new treatment for stroke patients. In this program NeuroVive\'s cyclosporin A for the treatment of neurological damage is combined with to-BBB\'s G-Technology® to enhance delivery of this drug across the blood-brain barrier. The strategic collaboration between the two companies commenced in October 2010 and the Eurostars grant solidifies and accelerates this partnership.
Others: NeuroVive Pharmaceutical and to-BBB, the Dutch brain drug delivery company, have been awarded a grant of €1 million through the Eureka Eurostars program for the joint development of therapies for stroke and other acute neurological conditions.
Therapeutic area: Cerebrovascular diseases - CNS diseases
